Pfizer Inc. has unveiled a significant advancement in their ongoing Phase 3 MONeT trial, specifically through a substudy aiming to evaluate the efficacy and safety of its RSV vaccine, ABRYSVO, in immunocompromised adults. Historically, this vulnerable population has faced severe complications from
Grail, a leading player in the cancer detection industry, is making a significant cut to its workforce, laying off approximately 350 employees, which represents about 25% of its total workforce. This substantial reduction is part of a major restructuring effort aimed at refocusing the company’s r
The U.S. Food and Drug Administration (FDA) has ushered in a new era in cancer treatment with the approval of Tecelra (afamitresgene autoleucel), an innovative therapy aimed at combating synovial sarcoma. This rare and aggressive form of cancer predominantly impacts young adults and has
The biotech landscape is abuzz with the launch of Red Queen Therapeutics, a startup that aims to revolutionize antiviral treatments. Backed by a $55 million investment from venture firm Apple Tree Partners and additional funding from the Biomedical Advanced Research and Development Authority
The recent collaboration between biotech creation engines Two River and Third Rock Ventures has led to the formation of TRC 2004, which has licensed a bispecific T-cell engager (BiTE) from Genor Biopharma. TRC 2004 has acquired the ex-China rights to the CD20/CD3-targeting BiTE, known as GB261,
The biotech industry has seen a flurry of activity, with companies undertaking significant workforce restructuring, achieving crucial FDA approvals, and navigating the complex landscape of clinical trials. These developments reflect both the challenges and advancements within the sector, offering a
